全球治疗诊断市场

到 2030 年，全球治疗诊断市场规模将达到 46 亿美元

全球诊疗市场规模预计在2024年为20亿美元，到2030年将达到46亿美元，在2024-2030年的分析期间内，复合年增长率为15.2%。诊疗仪器是本报告分析的细分市场之一，预计其复合年增长率为14.8%，到分析期末将达到27亿美元。诊疗试剂细分市场在分析期间的复合年增长率预计为16.3%。

美国市场规模估计为 5.406 亿美元，中国市场预计复合年增长率为 20.1%

预计到2024年，美国治疗诊断市场规模将达5.406亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到9.979亿美元，在2024-2030年的分析期间内，复合年增长率为20.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为11.2%和13.6%。在欧洲，预计德国市场的复合年增长率约为12.1%。

全球治疗诊断市场—主要趋势与驱动因素摘要

治疗诊断学是精准医疗的未来，还是只是一个开始？

诊疗学是诊断影像与标靶治疗的融合，是现代医疗保健领域最具创新性的趋势之一。这种方法使临床医生能够使用单一分子平台检测、监测和治疗疾病，通常结合放射性标记药物或伴随诊断来指导个人化治疗策略。诊疗最初专注于肿瘤学，尤其是前列腺肿瘤、甲状腺肿瘤和神经内分泌肿瘤，目前正迅速扩展到其他领域，包括心臟病学、神经病学和发炎性疾病。透过将分子诊断与标靶治疗相结合，这种双重功能模式正在重新定义慢性和危及生命的疾病的识别和治疗方式。

治疗诊断学在个人化治疗方面具有独特的能力。它能够即时回馈治疗效果、早期发现病情进展并快速调整治疗方法。这减少了无效治疗的机会，并将副作用降至最低。随着医疗保健逐渐走向个人化治疗模式，治疗诊断学提供了一种引人注目的替代方案，可以取代千篇一律的通讯协定。核子医学中采用镏-177 和镓-68 等辐射损伤治疗已在提高生存率和生活品质方面显示出良好的效果。这些发展也推动了监管部门的核准、对放射性药物製造的投资，以及肿瘤学家、放射科医生和分子生物学家之间的跨学科合作。

影像技术和放射性药物如何改善治疗结果？

诊疗的发展与核子成像技术的进步和新型放射性药物的研发密切相关。 PET（正子断层扫描）和 SPECT（单光子发射电脑断层扫描）影像已成为在分子层面上识别疾病生物标记的基石。当与对恶性细胞具有细胞毒性作用的标靶同位素结合时，这些诊断工具便成为治疗载体。锕-225 和镏-177 等 α 和 β 发射同位素的出现，为治疗抗药性癌症开闢了新的途径，同时最大限度地降低了全身毒性。

此外，伴随诊断技术正在与标靶治疗同步开发，以更准确地指南临床决策。 PSMA（前列腺特异性膜抗原）和生长抑制素受体等分子标记目前正被用于对患者进行分层、确定治疗合格以及监测治疗反应。使用迴旋加速器和发生器生产放射性同位素的兴起改善了这些药物的可近性，尤其是在社区和私人医疗机构。此外，奈米技术正在被探索用于封装和递送诊疗药物，从而增强肿瘤靶向性、降低肾毒性并延长循环时间。这些突破不仅改善了患者的预后，还使诊疗标准化，从而实现更广泛的临床应用。

治疗诊断学能否重塑癌症治疗的经济效益与疗效？

治疗诊断学正逐渐成为改善临床疗效并降低长期治疗成本的强大工具。透过及早识别疗效并精准施治，治疗诊断方案通常需要更少的治疗週期和更少的副作用，从而缩短住院时间并改善资源配置。随着精准医疗在全球蓬勃发展，治疗诊断学正被纳入癌症治疗演算法和临床路径。卫生技术评估 (HTA) 组织和付款方越来越认识到其经济价值，尤其是在转移性和晚期癌症领域，因为这些癌症的常规治疗回报有限。

基础建设投资正顺应此一趋势。医院和研究机构正在建立放射性药物生产能力​​，安装迴旋加速器和专门的影像实验室，以满足日益增长的诊疗需求。核子医学专家、医学物理学家和放射肿瘤学家的培训计画正在扩大，尤其是在欧洲、北美和亚太地区。同时，生物技术公司、放射性药物公司和学术中心之间的合作正在加速临床试验和註册申报。这种整合的生态系统正在为诊疗成为癌症治疗的标准组成部分奠定基础，使其不再只是最后的治疗或利基研究。

是什么推动了治疗诊断市场快速扩张？

诊疗市场的成长受到基于临床、技术和经济趋势的若干相互关联的因素所驱动。首先，癌症和神经退化性疾病的日益流行，促使医疗保健系统实施更精准、更有效率、更个人化的治疗方法。其次，放射性药物和伴随诊断技术的快速发展，推动了针对特异性疾病的疗法的开发，这些疗法具有双重功能，并能降低脱靶效应。

第三，核子医学摄影影像基础设施的改进，包括PET/SPECT扫描仪和数位影像平台的广泛普及，使得诊断引导治疗在已开发市场和新兴市场都更加便捷。第四，製药公司和政府机构加大精准医疗研究的投资，正在刺激产品线创新和临床试验的快速进展。第五，某些疗法（尤其是在肿瘤领域）的优惠监管和快速通道资格认定正在缩短上市时间并促进其商业性应用。最后，人工智慧和机器学习在影像解读和治疗计画中的整合，正在提高诊断准确性并优化治疗方案。这些因素共同作用，使治疗诊断成为下一代以患者为中心的医疗保健的重要组成部分。

部分

产品（诊疗设备、诊疗试剂、诊疗软体）、技术（基因组学技术、蛋白质组学技术、代谢体学技术、生物标记技术）、应用（肿瘤学应用、神经病学应用、循环系统应用、感染疾病应用）、最终用途（医院、诊断实验室、研究机构）

受访公司范例

• Abbott Laboratories
• Agilent Technologies
• Alpha9 Theranostics
• Bayer AG
• Beckman Coulter（Danaher）
• Cardinal Health
• Curium Pharma
• GE HealthCare
• Illumina Inc.
• Lantheus Holdings
• Molecular Theranostics LLC
• Myriad Genetics
• Novartis AG
• Pfizer Inc.
• Philips HealthCare
• Qiagen NV
• Radiopharm Theranostics（RAD）
• RaySearch Laboratories
• Siemens Healthineers
• Telix Pharmaceuticals

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Theranostics Market to Reach US$4.6 Billion by 2030

The global market for Theranostics estimated at US$2.0 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Theranostics Instruments, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Theranostics Reagents segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$540.6 Million While China is Forecast to Grow at 20.1% CAGR

The Theranostics market in the U.S. is estimated at US$540.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$997.9 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Theranostics Market - Key Trends & Drivers Summarized

Is Theranostics the Future of Precision Medicine, or Just the Start?

Theranostics, the fusion of diagnostic imaging and targeted therapy, represents one of the most transformative trends in modern healthcare. This approach enables clinicians to detect, monitor, and treat diseases using a single molecular platform, often with radiolabeled agents or companion diagnostics that guide personalized treatment strategies. While initially focused on oncology-particularly for prostate, thyroid, and neuroendocrine tumors-theranostics is rapidly expanding into other areas such as cardiology, neurology, and inflammatory diseases. By linking molecular diagnostics to targeted therapeutic delivery, this dual-function modality is redefining how chronic and life-threatening diseases are identified and treated.

What sets theranostics apart is its capacity for patient-specific treatment. It allows for real-time feedback on therapeutic efficacy, early detection of disease progression, and rapid adjustment of therapeutic regimens. This reduces exposure to ineffective therapies and minimizes side effects. As healthcare moves toward individualized treatment models, theranostics offers a compelling alternative to one-size-fits-all protocols. The adoption of radiotheranostic agents like Lutetium-177 and Gallium-68 in nuclear medicine has shown promising results in improving survival rates and quality of life. These developments are also accelerating regulatory recognition, investment in radiopharmaceutical production, and cross-disciplinary collaboration between oncologists, radiologists, and molecular biologists.

How Are Imaging Technologies and Radiopharmaceuticals Advancing Theranostic Efficacy?

The evolution of theranostics is closely linked to advances in nuclear imaging technologies and the development of novel radiopharmaceutical agents. PET (positron emission tomography) and SPECT (single-photon emission computed tomography) imaging have become cornerstones in identifying disease biomarkers at the molecular level. When paired with targeted isotopes that deliver cytotoxic effects to malignant cells, these diagnostic tools become therapeutic vectors. The increasing availability of alpha and beta-emitting isotopes-such as Actinium-225 and Lutetium-177-has opened new avenues for treating resistant cancers while minimizing systemic toxicity.

In addition, companion diagnostics are being developed alongside targeted therapies to guide clinical decisions with higher precision. Molecular markers such as PSMA (Prostate-Specific Membrane Antigen) and somatostatin receptors are now being used to stratify patients, determine eligibility for therapy, and monitor treatment response. The rise of cyclotron and generator-based radioisotope production is improving access to these agents, particularly in regional and private healthcare settings. Moreover, nanotechnology is being explored to encapsulate and deliver theranostic agents, offering enhanced tumor targeting, reduced renal toxicity, and prolonged circulation times. These breakthroughs are not only improving patient outcomes but also standardizing theranostics for broader clinical application.

Can Theranostics Reshape the Economics and Outcomes of Cancer Care?

Theranostics is emerging as a powerful tool for improving clinical outcomes while reducing long-term treatment costs-an increasingly important consideration in value-based healthcare systems. By identifying responders early and delivering therapy with high precision, theranostic regimens often require fewer treatment cycles and generate fewer side effects, resulting in shorter hospital stays and better resource allocation. As precision medicine initiatives gain traction globally, theranostics is being integrated into oncology treatment algorithms and clinical pathways. Health technology assessment (HTA) bodies and payers are gradually acknowledging its economic value, particularly in metastatic and late-stage cancers where traditional treatments offer diminishing returns.

Infrastructure investments are also following this trend. Hospitals and research institutions are building out radiopharmaceutical manufacturing capabilities, cyclotron installations, and specialized imaging labs to accommodate the rising demand for theranostic services. Training programs for nuclear medicine professionals, medical physicists, and theranostic oncologists are expanding, especially in Europe, North America, and Asia-Pacific. At the same time, collaborations between biotech firms, radiopharmaceutical companies, and academic centers are accelerating clinical trials and regulatory submissions. This integrated ecosystem is laying the groundwork for theranostics to become a standard component of cancer care rather than a last-resort treatment or research niche.

What’s Fueling the Rapid Expansion of the Theranostics Market?

The growth in the theranostics market is driven by several interconnected factors grounded in clinical, technological, and economic trends. First, the increased incidence of cancer and neurodegenerative diseases is prompting healthcare systems to adopt more precise, efficient, and personalized treatment modalities. Second, rapid advancements in radiopharmaceuticals and companion diagnostics are enabling the development of disease-specific theranostic agents that offer dual functionality with reduced off-target effects.

Third, improvements in nuclear imaging infrastructure-including broader deployment of PET/SPECT scanners and digital imaging platforms-are making diagnostic-guided therapy more accessible across both developed and emerging markets. Fourth, growing investments from pharmaceutical companies and government bodies in precision medicine research are fueling pipeline innovation and fast-tracking clinical trials. Fifth, favorable regulatory pathways and fast-track designations for certain theranostic drugs-especially in oncology-are reducing time-to-market and encouraging commercial uptake. Lastly, the integration of AI and machine learning in image interpretation and treatment planning is improving diagnostic accuracy and optimizing therapy delivery. Collectively, these drivers are positioning theranostics as a pivotal force in next-generation, patient-centered healthcare.

SCOPE OF STUDY:

The report analyzes the Theranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Theranostics Instruments, Theranostics Reagents, Theranostics Software); Technology (Genomics Technology, Proteomics Technology, Metabolomics Technology, Biomarkers Technology); Application (Oncology Application, Neurology Application, Cardiology Application, Infectious Diseases Application); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• Agilent Technologies
• Alpha9 Theranostics
• Bayer AG
• Beckman Coulter (Danaher)
• Cardinal Health
• Curium Pharma
• GE HealthCare
• Illumina Inc.
• Lantheus Holdings
• Molecular Theranostics LLC
• Myriad Genetics
• Novartis AG
• Pfizer Inc.
• Philips HealthCare
• Qiagen N.V.
• Radiopharm Theranostics (RAD)
• RaySearch Laboratories
• Siemens Healthineers
• Telix Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Theranostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Adoption of Personalized Medicine Drives Growth in Theranostic Platforms
  • Expansion of Companion Diagnostics in Oncology Enhances Targeted Drug Efficacy
  • Increased Use of Theranostics in Nuclear Medicine Supports Precision Imaging and Therapy
  • Integration of Diagnostic Imaging With Targeted Radiotherapy Boosts Clinical Workflow Efficiency
  • Growth in Radioisotope Development Enhances Dual-Function Diagnostic-Therapeutic Agents
  • Demand for Early Detection and Monitoring of Tumor Response Strengthens Theranostic Relevance
  • Increased Funding for Radiotheranostic Trials Expands Clinical Validation Across Cancer Types
  • Availability of PET/CT and SPECT Technologies Supports Platform Compatibility
  • Advancements in Molecular Imaging Tracers Improve Disease-Specific Targeting
  • Regulatory Fast-Tracking for Breakthrough Theranostic Drugs Encourages Market Entry
  • Adoption in Multi-Modal Oncology Clinics Supports Real-Time Treatment Optimization
  • Expansion of Biomarker-Guided Therapy in Autoimmune and Neurological Disorders Extends Market Potential
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Theranostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Theranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Theranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Theranostics Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Theranostics Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Theranostics Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Theranostics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Theranostics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Theranostics Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Theranostics Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Theranostics Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Theranostics Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Cardiology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Genomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Genomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Genomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Proteomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Proteomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Proteomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Metabolomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Metabolomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Metabolomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Biomarkers Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Biomarkers Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Biomarkers Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• JAPAN
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• CHINA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• EUROPE
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Theranostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Theranostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• FRANCE
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 110: France Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: France 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• GERMANY
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 146: UK Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Theranostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• INDIA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 221: India Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: India 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Theranostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Theranostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• AFRICA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030

IV. COMPETITION